Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
#updated 08/15/2022 User-agent: * Disallow: */jcr Disallow: /*.iframe.html Disallow: /*api Disallow: /*bin/ Disallow: /*bin/abbvieforms/refreshlogin Disallow: /DSARegistration Disallow: /_jcr_content/ Disallow: /api/* Disallow: /content/dam/formsanddocuments/ Disallow: /content/forms/af/ Disallow: /content/usergenerated/content/forms/af/ Disallow: /content/usergenerated/content/forms/af/* Disallow: /favicon.ico Disallow: /form-contact-a-rep/ Disallow: /form-financial-support/ Disallow: /generatepdf* Disallow: /jcr* Disallow: /landing* Disallow: /page-not-found* Disallow: /search-results* Disallow: /system-error* Disallow: /thank-you* Sitemap: www.linzesshcp.com/sitemap.xml # End |
Title | LINZESS® (linaclotide) | For HCPs | For IBS-C & CIC |
Description | Her IBS-C is more than Information for HCPs on LINZESS® (linaclotide), a prescription medication that treats Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation |
Keywords | Generic Indication |
WebSite | linzesshcp.com |
Host IP | 72.52.10.14 |
Location | United States |
Site | Rank |
US$11,799,722
Last updated: 2023-04-28 08:20:39
linzesshcp.com has Semrush global rank of 896,996. linzesshcp.com has an estimated worth of US$ 11,799,722, based on its estimated Ads revenue. linzesshcp.com receives approximately 1,361,507 unique visitors each day. Its web server is located in United States, with IP address 72.52.10.14. According to SiteAdvisor, linzesshcp.com is safe to visit. |
Purchase/Sale Value | US$11,799,722 |
Daily Ads Revenue | US$10,893 |
Monthly Ads Revenue | US$326,762 |
Yearly Ads Revenue | US$3,921,139 |
Daily Unique Visitors | 90,768 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
linzesshcp.com. | A | 300 | IP: 72.52.10.14 |
linzesshcp.com. | NS | 86400 | NS Record: ha3.markmonitor.zone. |
linzesshcp.com. | NS | 86400 | NS Record: ha4.markmonitor.zone. |
linzesshcp.com. | NS | 86400 | NS Record: ha1.markmonitor.zone. |
linzesshcp.com. | NS | 86400 | NS Record: ha2.markmonitor.zone. |
linzesshcp.com. | MX | 14400 | MX Record: 10 mxb-0015e701.gslb.pphosted.com. |
linzesshcp.com. | MX | 14400 | MX Record: 10 mxa-0015e701.gslb.pphosted.com. |
linzesshcp.com. | TXT | 3600 | TXT Record: tb95klrw59fh3l6zj5967kr563xyg2b3 |
linzesshcp.com. | TXT | 3600 | TXT Record: v=spf1 mx include:spf-0015e701.pphosted.com ~all |
linzesshcp.com. | TXT | 3600 | TXT Record: google-site-verification=LZKtQLzet7qgXI0dpi3vMdFWwfB8e86j3s9s-1b1njw |
AbbVie Access Important Safety Information Prescribing Information Patient Site ABOUT LINZESS MOA DOSING LINZESS FOR IBS-C EFFICACY SAFETY IBS-C PATIENT IDENTIFICATION LINZESS FOR CIC EFFICACY SAFETY CIC PATIENT IDENTIFICATION SUPPORT SAMPLES & SAVINGS COVERAGE REQUEST A REP ADDITIONAL RESOURCES PATIENT SITE LINZESS ® (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). 1 Her IBS-C is more than constipation Choose LINZESS to help relieve constipation and overall abdominal symptoms (bloating, pain, and discomfort). 1 Why wait? Not an actual patient. EFFICACY DATA SAFETY DATA PATIENT SAVINGS EFFICACY DATA SAFETY DATA PATIENT SAVINGS IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE LINZESS is contraindicated in patients less than 2 years of age; in nonclinical studies in neonatal mice, administration of a single, |
HTTP/1.1 301 Moved Permanently cache-control: no-cache, no-store, must-revalidate Pragma: no-cache Expires: -1 X-XSS-Protection: 1; mode=block X-Content-Type-Options: nosniff X-Frame-Options: DENY Content-Security-Policy: script-src 'self' Location: https://www.linzesshcp.com/ Vary: Accept Content-Type: text/plain; charset=utf-8 Content-Length: 61 Date: Thu, 21 Oct 2021 11:29:44 GMT Connection: keep-alive Set-Cookie: NSC_us_nbsl-83+63+21+25-91=ffffffff2fe62ef045525d5f4f58455e445a4a423660;path=/;httponly HTTP/1.1 200 OK Content-Type: text/html; charset=utf-8 Content-Length: 37685 Connection: keep-alive Date: Thu, 21 Oct 2021 11:30:47 GMT Cache-Control: no-cache, no-store Expires: -1 Pragma: no-cache Set-Cookie: ASP.NET_SessionId=jj3krlo1naocnspxyrwzrv4c; path=/; HttpOnly; SameSite=Lax Set-Cookie: SC_ANALYTICS_GLOBAL_COOKIE=bf88f9f5ec9547e6943a35440f6f703b|False; path=/; HttpOnly Strict-Transport-Security: max-age=31536000 X-Content-Type-Options: nosniff Server: Vary: Accept-Encoding,Accept-Encoding X-Cache: Miss from cloudfront Via: 1.1 91e7f6dd5130ccc0c1247b2da038e3de.cloudfront.net (CloudFront) X-Amz-Cf-Pop: ORD52-C2 X-Amz-Cf-Id: Xhyc-uOXsBzSjZteM2SqXQliSxdAYWNU7y86GU80w1WzC1YOLgEfmA== |
Domain Name: LINZESSHCP.COM Registry Domain ID: 1741200394_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.markmonitor.com Registrar URL: http://www.markmonitor.com Updated Date: 2021-07-27T09:20:38Z Creation Date: 2012-08-28T18:36:24Z Registry Expiry Date: 2022-08-28T18:36:24Z Registrar: MarkMonitor Inc. Registrar IANA ID: 292 Registrar Abuse Contact Email: abusecomplaints@markmonitor.com Registrar Abuse Contact Phone: +1.2083895740 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: HA1.MARKMONITOR.ZONE Name Server: HA2.MARKMONITOR.ZONE Name Server: HA3.MARKMONITOR.ZONE Name Server: HA4.MARKMONITOR.ZONE DNSSEC: unsigned >>> Last update of whois database: 2021-09-10T05:15:13Z <<< |